Adjusted EBITDA - filings, earnings calls, financial reports, news

Adjusted EBITDA

Search documents

Canopy Growth(CGC) - 2026 Q3 - Earnings Call Transcript

2026-02-06 16:02

Financial Data and Key Metrics Changes - Canopy Growth ended Q3 with CAD 371 million in cash and cash equivalents, and a net cash position of CAD 146 million, marking a strong financial foundation [4][10] - The company achieved its slimmest Adjusted EBITDA loss to date of CAD 3 million, reflecting improved cost discipline and execution [14] - Q3 cannabis net revenue was CAD 52 million, up 4% year-over-year, with Canadian medical cannabis revenue increasing 15% to CAD 23 million [11][12] Business Line Data and Key Metrics Changes - Canadian medical cannabis net revenue grew 15% year-over-year, marking the sixth consecutive quarter of growth, driven by high-quality patient experiences and engagement [6] - Canadian adult use cannabis revenue increased 8% year-over-year to CAD 23 million, supported by growth in pre-rolls and vapes [12] - Storz & Bickel net revenue grew 45% sequentially to CAD 23 million, driven by strong seasonal sales and the introduction of new products [13] Market Data and Key Metrics Changes - International cannabis sales increased 22% quarter-over-quarter, indicating stabilization and return to growth [12] - The company is focusing on improving execution and laying groundwork for growth in international markets, particularly in Europe [8] Company Strategy and Development Direction - Canopy Growth is focused on elevating the quality of its brands, strengthening product innovation, and improving cultivation efficiency [7][19] - The proposed acquisition of MTL Cannabis is expected to enhance the company's leadership in Canadian medical cannabis and provide high-quality flower supply [5][6] - The company aims to achieve positive Adjusted EBITDA during fiscal 2027, supported by cost-saving initiatives and growth in Canadian cannabis sales [10][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's progress, highlighting a stronger balance sheet and growing Canadian cannabis sales [9] - The focus is on unlocking additional value through elevated cultivation, innovative brands, and disciplined execution [9][19] - Management is actively addressing potential impacts from proposed changes to the Veterans Reimbursement Program while maintaining service quality [6][32] Other Important Information - The company completed a CAD 150 million recapitalization to improve liquidity and extend debt maturities to 2031, providing more flexibility for future financing [5][11] - The integration of MTL Cannabis is expected to contribute positively to net revenue, gross margin, and Adjusted EBITDA [16] Q&A Session Summary Question: Expectations for international business growth over the next 12-18 months - Management indicated that they are confident in improving international supply chain capabilities and expanding flower offerings in Europe [21][22] Question: Trends in gross margin expectations for cannabis - Management expects a blended gross margin in the mid- to high 30s, with the MTL acquisition anticipated to be accretive to gross margin [25][26] Question: Clarification on positive Adjusted EBITDA expectations - Management aims for positive Adjusted EBITDA during fiscal 2027, with efforts to achieve this as soon as possible [29] Question: Impact of debt maturities and equity issuance - Management expects reduced utilization of the ATM in the coming quarters due to improved balance sheet position [30] Question: Domestic medical business and veterans reimbursement proposal - Management is actively working to mitigate the impact of proposed reimbursement changes on veterans while maintaining service quality [32][34]